<p>如果你在 20 多歲，你可能還有超過四十年的時間可以投資，直到退休。有些人可能會建議現在是採取激進投資立場的時候，但這可能意味着比你想象的更大的風險。對錯誤的股票進行大額投資，你可能會把數千美元變成幾分錢。</p>
<p>一個更合理的選擇可能是尋找一組在本質上具有增長潛力的行業領導者進行投資。醫療保健行業就是一個很好的例子，因為每個人都需要醫療服務，而技術進步推動了該行業的增長。而且，幸運的是，行業領導者 <strong>Medtronic</strong>(MDT -0.71%)、<strong>Johnson &amp; Johnson</strong>(JNJ -0.57%) 和 <strong>Merck</strong>(MRK 0.34%) 目前的價格都很有吸引力。</p>
<p>以下是年輕投資者可能想要購買這三隻醫療保健股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. Medtronic 正在進行一些正常的維護</h2>
<p>Medtronic 是全球最大的醫療設備製造商之一。它在心血管、神經科學、外科醫療和糖尿病領域佔據行業領先地位。公司的增長停滯不前。這使得華爾街對其股票持悲觀態度，股價比 2021 年的高點下跌了約 30%。目前的股息收益率接近歷史高點，約為 3%。</p>
<p>為什麼要購買這隻低迷的股票？因為 Medtronic 有着在每家公司最終都必須面對的艱難時期中生存下來的悠久歷史。其連續 48 年的年度股息增長就是證明。這是一個令人難以置信的記錄，使得該公司距離股息之王的地位僅差兩年。然而，更重要的是，管理層正在採取必要措施來改善盈利能力。這包括削減成本、投資新技術和產品，以及將業務重心重新聚焦於最盈利的運營。下一步是公司糖尿病業務的分拆，預計將在 2026 年初進行。</p>
<p>如果你不介意從一家懂得如何在艱難時期生存的公司收取高額收益，Medtronic 是一個很好的選擇，無論你是 20 歲還是 65 歲。但如果你 20 歲，你可以受益於數十年的業務增長，並利用股息再投資計劃進一步複利你的回報。</p>
<h2>2. Johnson &amp; Johnson 將渡過滑石粉危機</h2>
<p>接下來是 Johnson &amp; Johnson，這是一家在製藥和醫療設備領域的巨頭。與 Medtronic 一樣，它在投資者中也不受歡迎。該股票的股息收益率為 3%，處於歷史收益範圍的高位。平均製藥股票的收益率約為 1.4%，而平均醫療保健股票的收益率大約為 1.8%。</p>
<p>然而，股價並沒有像 Medtronic 那樣低迷，J&amp;J 的股價比歷史最高點下跌了大約 5%。不過，這裏存在一個實質性的負擔，即針對 J&amp;J 提起的滑石粉訴訟。涉及數十億美元的賠償，公司無法完全與股東討論這個問題，因為這是法律性質的問題。這種不確定性使得 J&amp;J 的股票略顯疲軟。但這位股息之王已經連續六十多年每年增加股息，清楚地表明它知道如何在艱難時期生存。</p>
<p>公平地説，公司核心業務也面臨一些逆風。包括專利到期和需要不斷推出新藥和醫療設備。但這些只是正常的商業波動，類似於 Medtronic 所面臨的情況。加上法律問題，可能使得 J&amp;J 更適合激進投資者或那些能夠長期持有的投資者，比如 20 多歲的投資者。</p>
<h2>3. Merck 面臨專利懸崖</h2>
<p>Medtronic 專注於醫療設備。Johnson &amp; Johnson 的專長是醫療設備和藥物。Merck 則專注於藥物。儘管它的年度股息增長曆史不如前兩者長，僅有 15 年，但 Merck 的股息在幾十年中總體上呈上升趨勢。雖然在股息方面它並不完全與 Medtronic 和 J&amp;J 平起平坐，但它仍然是一家可靠的企業，證明了它能夠在艱難時期中生存。</p>
<p>不過，它目前正面臨困難。首先，市場對醫療公司的看法相對消極，涉及當前政府的政治和社會問題。考慮到醫療保健的重要性，尤其是藥物，這種情況可能會過去。Merck 的第二個問題是，其增長在很大程度上受到一種腫瘤藥物 -- Keytruda 的影響。然而，在幾年後，這種藥物將失去專利保護，Merck 需要有其他藥物準備好，以彌補仿製藥可能帶走的收入。Merck 的產品管線看起來有些薄弱，因此投資者擔心它無法應對即將到來的專利懸崖。</p>
<p>這並不是不合理，但 Merck 擁有世界級的研發團隊，而且它足夠大，可以收購擁有有吸引力產品的小型競爭對手（如果需要的話）。它很可能會找到解決專利問題的方法，就像它以前多次做到的那樣。不過，目前投資者情緒低迷，股價比 2024 年的高點下跌了近 40%，而股息收益率則處於歷史高位，約為 4%。如果你有時間的優勢，可以現在購買，並舒適地等待更好的日子。</p>
<h2>醫療保健故事的關鍵</h2>
<p>在醫療保健行業有兩種主要的投資方式。你可以選擇高風險高回報，投資那些擁有新穎產品的小型初創公司，希望你選擇的公司能夠在市場中獲勝。或者，你可以購買那些行業領導者，這些公司已經多次證明它們有能力在長期內生存和發展，通常還會收購初創公司以受益於它們的新產品。</p>
<p>大多數投資者更適合關注行業領導者。而且，通常購買行業領導者的最佳時機是當投資者對其前景感到悲觀的時候。今天的情況正是如此，醫療巨頭美敦力、強生和默克正面臨這樣的情形。如果你在 20 多歲時買入並持有直到退休（希望在此期間不斷再投資股息），歷史表明你將成為一位非常滿意的股東。</p>

強生

<p>文章建議 20 多歲的年輕投資者考慮購買三隻醫療保健股票：美敦力（Medtronic）、強生（Johnson & Johnson）和默克（Merck）。儘管美敦力最近面臨一些困難，但其提供了強勁的股息收益率，並正在重新聚焦於盈利能力。強生雖然面臨法律挑戰，但在股息增長方面有着悠久的歷史。默克主要是一家制藥公司，雖然也很可靠，但由於依賴單一藥物而面臨增長挑戰。總體而言，這些股票在醫療保健行業中為長期增長奠定了良好的基礎</p>

<p>If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but that could entail more risk than you think. Make a big bet on the wrong stock and you could turn thousands of dollars into pennies.</p>
<div class="lb-trans"><p>如果你在 20 多歲，你可能還有超過四十年的時間可以投資，直到退休。有些人可能會建議現在是採取激進投資立場的時候，但這可能意味着比你想象的更大的風險。對錯誤的股票進行大額投資，你可能會把數千美元變成幾分錢。</p>
</div><p>An alternative path that might make more sense is to find a collection of industry leaders in an inherently growth-oriented industry to invest in. The healthcare industry is a great example, since everyone needs medical care and technological advances drive the sector's growth. And, lucky for you, industry leaders <strong>Medtronic</strong>(MDT -0.71%), <strong>Johnson &amp; Johnson</strong>(JNJ -0.57%), and <strong>Merck</strong>(MRK 0.34%) are all attractively priced right now.</p>
<div class="lb-trans"><p>一個更合理的選擇可能是尋找一組在本質上具有增長潛力的行業領導者進行投資。醫療保健行業就是一個很好的例子，因為每個人都需要醫療服務，而技術進步推動了該行業的增長。而且，幸運的是，行業領導者 <strong>Medtronic</strong>(MDT -0.71%)、<strong>Johnson &amp; Johnson</strong>(JNJ -0.57%) 和 <strong>Merck</strong>(MRK 0.34%) 目前的價格都很有吸引力。</p>
</div><p>Here's why younger investors might want to buy all three of these healthcare stocks.</p>
<div class="lb-trans"><p>以下是年輕投資者可能想要購買這三隻醫療保健股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828591%2F21_11_11-a-person-pointing-to-a-wristwatch-_gettyimages-1175205904.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. Medtronic is taking care of some normal maintenance</h2>
<div class="lb-trans"><h2>1. Medtronic 正在進行一些正常的維護</h2>
</div><p>Medtronic is one of the largest medical device makers on the planet. It has industry-leading positions in the cardiovascular, neuroscience, medical surgical, and diabetes niches. The company's growth has stalled out. That has left Wall Street downbeat on the shares, which trade down around 30% from their 2021 highs. The dividend yield is near historical highs at around 3%.</p>
<div class="lb-trans"><p>Medtronic 是全球最大的醫療設備製造商之一。它在心血管、神經科學、外科醫療和糖尿病領域佔據行業領先地位。公司的增長停滯不前。這使得華爾街對其股票持悲觀態度，股價比 2021 年的高點下跌了約 30%。目前的股息收益率接近歷史高點，約為 3%。</p>
</div><p>Why buy this down-and-out stock? Because Medtronic has a long history of surviving through the hard times that every company eventually has to face. The proof of this is its 48 consecutive years' worth of annual dividend increases. That's an incredible streak that places the company just two years shy of Dividend King status. More important today, however, is that management is taking the steps necessary to improve profitability. That includes cutting costs, investing in new technologies and products, and refocusing its business around its most profitable operations. The next big move is the spin-off of the company's diabetes business, which is set to take place in early 2026.</p>
<div class="lb-trans"><p>為什麼要購買這隻低迷的股票？因為 Medtronic 有着在每家公司最終都必須面對的艱難時期中生存下來的悠久歷史。其連續 48 年的年度股息增長就是證明。這是一個令人難以置信的記錄，使得該公司距離股息之王的地位僅差兩年。然而，更重要的是，管理層正在採取必要措施來改善盈利能力。這包括削減成本、投資新技術和產品，以及將業務重心重新聚焦於最盈利的運營。下一步是公司糖尿病業務的分拆，預計將在 2026 年初進行。</p>
</div><p>If you don't mind collecting a lofty yield from a company that knows how to survive hard times, Medtronic is a great pick if you are 20 or 65. But if you are 20, you can benefit from decades of business growth and use a dividend reinvestment plan to further compound your returns.</p>
<div class="lb-trans"><p>如果你不介意從一家懂得如何在艱難時期生存的公司收取高額收益，Medtronic 是一個很好的選擇，無論你是 20 歲還是 65 歲。但如果你 20 歲，你可以受益於數十年的業務增長，並利用股息再投資計劃進一步複利你的回報。</p>
</div><h2>2. Johnson &amp; Johnson will survive the talcum powder mess</h2>
<div class="lb-trans"><h2>2. Johnson &amp; Johnson 將渡過滑石粉危機</h2>
</div><p>Next up on this list is Johnson &amp; Johnson, which is a giant in both the pharmaceutical and medical device spaces. Like Medtronic, it is out of favor with investors. The stock's dividend yield is 3% and toward the high side of the historical yield range. The average pharmaceutical stock has a yield of around 1.4% while the average healthcare stock's yield is roughly 1.8%.</p>
<div class="lb-trans"><p>接下來是 Johnson &amp; Johnson，這是一家在製藥和醫療設備領域的巨頭。與 Medtronic 一樣，它在投資者中也不受歡迎。該股票的股息收益率為 3%，處於歷史收益範圍的高位。平均製藥股票的收益率約為 1.4%，而平均醫療保健股票的收益率大約為 1.8%。</p>
</div><p>The stock price, however, isn't quite as downtrodden as that of Medtronic, with J&amp;J's price down from its all-time high by roughly 5% or so. That said, there is a material overhang here in the form of talcum powder lawsuits that have been filed against J&amp;J. There are billions of dollars at stake, and the company can't fully discuss the issue with shareholders because of the legal nature of the problem. The uncertainty has left J&amp;J shares to languish a bit. But this Dividend King has increased its dividend annually for over six consecutive decades, showing clearly that it knows how to survive hard times.</p>
<div class="lb-trans"><p>然而，股價並沒有像 Medtronic 那樣低迷，J&amp;J 的股價比歷史最高點下跌了大約 5%。不過，這裏存在一個實質性的負擔，即針對 J&amp;J 提起的滑石粉訴訟。涉及數十億美元的賠償，公司無法完全與股東討論這個問題，因為這是法律性質的問題。這種不確定性使得 J&amp;J 的股票略顯疲軟。但這位股息之王已經連續六十多年每年增加股息，清楚地表明它知道如何在艱難時期生存。</p>
</div><p>To be fair, there are also headwinds to deal with in the company's core operations. The list includes patent expirations and the need to keep bringing out new drugs and medical devices. But those are just normal business fluctuations, much like what Medtronic is dealing with. Adding the legal issue probably makes J&amp;J more appropriate for aggressive investors or those who can stick around for a long time. Like investors in their 20's.</p>
<div class="lb-trans"><p>公平地説，公司核心業務也面臨一些逆風。包括專利到期和需要不斷推出新藥和醫療設備。但這些只是正常的商業波動，類似於 Medtronic 所面臨的情況。加上法律問題，可能使得 J&amp;J 更適合激進投資者或那些能夠長期持有的投資者，比如 20 多歲的投資者。</p>
</div><h2>3. Merck has a patent cliff coming up</h2>
<div class="lb-trans"><h2>3. Merck 面臨專利懸崖</h2>
</div><p>Medtronic is focused on medical devices. Johnson &amp; Johnson's specialties are medical devices and drugs. Merck is just drugs. And while it doesn't have as long a history of annual dividend increases, at just 15 years, Merck's dividend has trended generally higher for decades. It doesn't exactly stand toe to toe with Medtronic and J&amp;J on the dividend front, but it is still a reliable business that has proven it can muddle through hard times.</p>
<div class="lb-trans"><p>Medtronic 專注於醫療設備。Johnson &amp; Johnson 的專長是醫療設備和藥物。Merck 則專注於藥物。儘管它的年度股息增長曆史不如前兩者長，僅有 15 年，但 Merck 的股息在幾十年中總體上呈上升趨勢。雖然在股息方面它並不完全與 Medtronic 和 J&amp;J 平起平坐，但它仍然是一家可靠的企業，證明了它能夠在艱難時期中生存。</p>
</div><p>It is facing a hard time right now. First, there's a rather negative view of healthcare companies in the market related to political and social issues involving the current administration. Given the importance of healthcare in general, and drugs in particular, this will likely pass. The second problem for Merck is that its growth is heavily influenced by one oncology drug -- Keytruda. In a few years, however, this drug will lose patent protections and Merck will need to have other drugs lined up to make up for the revenue that generic drugs tend to steal away. Merck's pipeline looks a bit weak, so investors are worried it won't be ready for the approaching patent cliff.</p>
<div class="lb-trans"><p>不過，它目前正面臨困難。首先，市場對醫療公司的看法相對消極，涉及當前政府的政治和社會問題。考慮到醫療保健的重要性，尤其是藥物，這種情況可能會過去。Merck 的第二個問題是，其增長在很大程度上受到一種腫瘤藥物 -- Keytruda 的影響。然而，在幾年後，這種藥物將失去專利保護，Merck 需要有其他藥物準備好，以彌補仿製藥可能帶走的收入。Merck 的產品管線看起來有些薄弱，因此投資者擔心它無法應對即將到來的專利懸崖。</p>
</div><p>That's not unreasonable, but Merck has world-class R&amp;D teams, and it is large enough to buy smaller competitors with attractive products (if it needs to). It is highly likely that it figures out how to deal with the patent issue, like it has many times before. Still, investors are downbeat at the moment, and the stock is off its 2024 highs by nearly 40% and the dividend yield is a historically high 4% or so. If you have the benefit of time, you can buy now and comfortably wait for better days.</p>
<div class="lb-trans"><p>這並不是不合理，但 Merck 擁有世界級的研發團隊，而且它足夠大，可以收購擁有有吸引力產品的小型競爭對手（如果需要的話）。它很可能會找到解決專利問題的方法，就像它以前多次做到的那樣。不過，目前投資者情緒低迷，股價比 2024 年的高點下跌了近 40%，而股息收益率則處於歷史高位，約為 4%。如果你有時間的優勢，可以現在購買，並舒適地等待更好的日子。</p>
</div><h2>The key to the healthcare story</h2>
<div class="lb-trans"><h2>醫療保健故事的關鍵</h2>
</div><p>There are two broad ways to play the healthcare sector. You can swing for the fences and buy small upstarts with novel products, hoping that the companies you pick are the ones that end up winning in the market. Or you can buy industry leaders that have proven time and again that they have the wherewithal to survive and thrive over the long term, often buying up the upstarts to benefit from their novel products.</p>
<div class="lb-trans"><p>在醫療保健行業有兩種主要的投資方式。你可以選擇高風險高回報，投資那些擁有新穎產品的小型初創公司，希望你選擇的公司能夠在市場中獲勝。或者，你可以購買那些行業領導者，這些公司已經多次證明它們有能力在長期內生存和發展，通常還會收購初創公司以受益於它們的新產品。</p>
</div><p>Most investors will be better off focusing on the industry leaders. And, often, the best time to buy industry leaders is when investors are downbeat on their prospects. Which is exactly the case today with industry giants Medtronic, Johnson &amp; Johnson, and Merck. If you buy in while you are in your 20s and hold until you retire (hopefully reinvesting dividends all along the way), history suggests you will end up a very happy shareholder.</p>
<div class="lb-trans"><p>大多數投資者更適合關注行業領導者。而且，通常購買行業領導者的最佳時機是當投資者對其前景感到悲觀的時候。今天的情況正是如此，醫療巨頭美敦力、強生和默克正面臨這樣的情形。如果你在 20 多歲時買入並持有直到退休（希望在此期間不斷再投資股息），歷史表明你將成為一位非常滿意的股東。</p>
</div>

如果你處於 20 多歲的年齡段，可以考慮購買這三隻醫療保健股票